LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1
Authors
Keywords
-
Journal
Cancer Cell International
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-15
DOI
10.1186/s12935-020-01481-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KCNQ1OT1/miR-217/ZEB1 feedback loop facilitates cell migration and epithelial-mesenchymal transition in colorectal cancer
- (2019) Yinzhu Bian et al. CANCER BIOLOGY & THERAPY
- lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway
- (2019) Yongchao Li et al. OncoTargets and Therapy
- Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
- (2019) Xiangfeng Shen et al. Frontiers in Immunology
- Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
- (2019) Meenal Sharma et al. MEDICINE
- PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
- (2018) Xin Yao Qiu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-β signaling pathway
- (2018) Wei Jin et al. BIOMEDICINE & PHARMACOTHERAPY
- Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression
- (2018) Kimberley Kolijn et al. CANCER RESEARCH
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling
- (2018) Shanyi Zhang et al. Cell Death & Disease
- PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
- (2018) Pedro Isaacsson Velho et al. Expert Review of Clinical Pharmacology
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis
- (2018) Hongwei Sun et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- YY1-induced upregulation of lncRNA KCNQ1OT1 regulates angiotensin II-induced atrial fibrillation by modulating miR-384b/CACNA1C axis
- (2018) Caijie Shen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Dysregulated Expression of KCNQ1OT1 and Its Interaction with Downstream Factors miR-145/CCNE2 in Breast Cancer Cells
- (2018) Weiliang Feng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The miR-15a/16 gene cluster in human cancer: A systematic review
- (2018) Ting Liu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis
- (2018) Zhiwu Dong et al. JOURNAL OF CELLULAR PHYSIOLOGY
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
- (2017) Steven C. Kao et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Differential methylation of lncRNA KCNQ1OT1 promoter polymorphism was associated with symptomatic cardiac long QT
- (2017) Eliecer Coto et al. Epigenomics
- The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
- (2017) Nora Ness et al. Oncotarget
- Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
- (2017) Song Xue et al. Oncotarget
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries
- (2016) Martin C.S. Wong et al. EUROPEAN UROLOGY
- PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
- (2016) Chan-Young Ock et al. Oncotarget
- Positive feedback regulation between IL10 and EGFR promotes lung cancer formation
- (2016) Tsung-I Hsu et al. Oncotarget
- PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
- (2016) Heidrun Gevensleben et al. Oncotarget
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- Regulation of functional KCNQ1OT1 lncRNA by β-catenin
- (2016) Naohiro Sunamura et al. Scientific Reports
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- PD-1 and PD-L1 antibodies for melanoma
- (2015) Katy K Tsai et al. Human Vaccines & Immunotherapeutics
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers
- (2011) Kati P. Porkka et al. GENES CHROMOSOMES & CANCER
- Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer
- (2011) M Musumeci et al. ONCOGENE
- miR-15a and miR-16-1 in cancer: discovery, function and future perspectives
- (2009) R I Aqeilan et al. CELL DEATH AND DIFFERENTIATION
- The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
- (2008) Désirée Bonci et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started